Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.52 |
| ▸ | NPY4R | P50391 | 13/20 | 0.43 |
| ▸ | NPY1R | P25929 | 9/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.43 |
| ▸ | NPY2R | P49146 | 5/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31454130 | 1.00 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL2490761 | 1.00 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29787128 | 1.00 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29697052 | 1.00 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL4587351 | 0.99 | NOD1 (0.51) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL2811179 | 0.99 | NOD1 (0.51) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| Hydrochloric Acid SCHEMBL9186802 | 0.99 | NOD1 (0.51) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL23286096 | 0.97 | NOD1 (0.50) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL1711608 | 0.97 | NOD1 (0.50) | NOD1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL1711604 | 0.97 | NOD1 (0.50) | NOD1NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | claimed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | claimed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | claimed |
| EP-0502007-A4 | METHOD FOR REDUCING BLOOD CHOLESTEROL USING ARGININE | — | 1992-11-19 | — | — | EP | claimed |
| US-5157022-A | Administering arginine nicotinate and di- and tripeptides of arginine | BARBUL ADRIAN (US) | 1992-10-20 | — | — | US | claimed |
| EP-0502007-A1 | ARGININE NICOTINATE FOR REDUCING BLOOD CHOLESTEROL | BARBUL, Adrian (US) | 1992-09-09 | — | — | EP | claimed |
| WO-1991007188-A1 | METHOD FOR REDUCING BLOOD CHOLESTEROL USING ARGININE | BARBUL ADRIAN (US) | 1991-05-30 | — | — | WO | claimed |
| WO-2022204461-A1 | KITS, COMPOSITIONS, AND METHODS OF TREATING HAIR LOSS | ANDREWS NICK (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-2925771-B1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL SCIENT IND RES (IN) | 2021-08-18 | — | — | EP | disclosed |
| CN-111896655-A | Method for analyzing and exploring functional metabolites produced by probiotics in digestive tract | 中国农业大学 | 2020-11-06 | — | — | CN | disclosed |
| US-9751911-B2 | Solomonamide analogue compounds, pharmaceuticals containing solomonamide analogue compounds, and processes for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-09-05 | — | — | US | disclosed |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | disclosed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | disclosed |
| US-7186687-B2 | Compositions and methods for treatment of Psoriasis | PROCYTE CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-6967096-B2 | Enzymatic peptide for use in for use in the treatment of Alzheimer's disease | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-11-22 | — | — | US | disclosed |
| US-20020106779-A1 | Thermostable peptidase | CALIFORNIA INSTITUTE OF TECHNOLOGY, A CALIFORNIA CORPORATION | 2002-08-08 | — | — | US | disclosed |
| US-6294367-B1 | NUCLEOTIDE SEQUENCES CODING ENZYMATIC POLYPEPTIDE; FOR USE IN SEQUENCE DETERMINATION OF POLYPEPTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2001-09-25 | — | — | US | disclosed |
| WO-1989007604-A1 | NOVEL GENES AND PLASMIDS AND TRANSFORMED BACTERIA CREATED THEREFROM | THE ROCKEFELLER UNIVERSITY (US) | 1989-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | CNR2, SRM, CNR1 | NOD1 269/4885NPY4R 2890/4885NPY1R 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.